Prescribing information

 

   

TAFINLAR (dabrafenib) + MEKINIST (trametinib) indications:1,2

Melanoma

Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Adjuvant treatment of melanoma

Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

Non-small cell lung cancer (NSCLC)

Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer BRAF V600 mutation.

 

DURABLE Five-Year Survival Benefit3

TAFINLAR + MEKINIST showed DURABLE responses up to five years in adult patients with BRAF V600-positive unresectable or metastatic melanoma3

 

Key Clinical Data Insights From COMBI-v and COMBI-d

The efficacy and safety of TAFINLAR+MEKINIST for the treatment of adult patients with BRAF V600-positive unresectable or metastatic melanoma has been studied in two large Phase III trials: COMBI-v (vs. vemurafenib) and COMBI-d (vs. dabrafenib).4–6 A pooled analysis was performed on the data from the TAFINLAR + MEKINIST treatment arms of these two trials. In a landmark five-year analysis of the trials, TAFINLAR + MEKINIST demonstrated that:

More than one in three (34%) patients treated with TAFINLAR + MEKINIST were alive at five years.3

 

More than half (55%) of patients with low tumour burden (normal LDH and <3 disease sites) treated with TAFINLAR + MEKINIST were alive at five years.3

 

Nearly one in five (19%) patients treated with TAFINLAR + MEKINIST were still progression-free at five years.3

 

Complete response* is possible for nearly one in five (19%) patients treated with TAFINLAR + MEKINIST – for those patients with a complete response to treatment, overall survival (OS) was 71% and progression-free survival (PFS) was 49% at five years.3

 

Patients with favourable prognostic factors (normal LDH, <3 disease sites, ECOG performance status of 0) were more likely to achieve complete response and long-term overall survival than the overall population.3

 

 

Please visit the COMBI-v efficacy, COMBI-d efficacy and pooled safety pages for further information on the two trials.

The pooled population consisted of 563 first-line adult patients with BRAF V600-positive unresectable or metastatic melanoma. All patients in the analysis had been randomised to receive TAFINLAR 150 mg BID + MEKINIST 2 mg QD in either COMBI-v or COMBI-d. Median follow-up was 22 months (range, 0–76).3

Image of chart detailing COMBI-v and COMBI-d Study Design

 

*Indicates best overall response achieved at any point during the trials.

BID, twice daily; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; QD, once daily; R, randomised.

References

  1. TAFINLAR (dabrafenib). Summary of Product Characteristics.
  2. MEKINIST (trametinib). Summary of Product Characteristics.
  3. Robert C, et al. N Engl J Med 2019;381:626–636.
  4. Robert C, et al. N Engl J Med 2015;372:30–39.
  5. Long G, et al. N Engl J Med 2014;371:1877–1888.
  6. Long G, et al. Lancet 2015;386:444–451.
  7. Robert C, et al. Pigment Cell Melanoma Res 2018;31:201.
Rate this content: 
Average: 4 (1 vote)
UK | August 2023 | 100912-2

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]